Section 32: Steven Kafka
Former Foundation Medicine President and COO Steven Kafka has joined venture capital fund Section 32 as a managing partner. He is currently executive chairman at Thrive Earlier Detection and at ArcherDX and will continue in these roles. He joins Section 32 from Third Rock Ventures, where he was a partner and venture partner and which he joined after leaving Foundation Medicine. Prior to that, he worked at Aileron Therapeutics, Infinity Pharmaceuticals, Millennium Pharmaceuticals, Strategic Decisions Group, and Forrester Research. Kafka holds a PhD in political economy and government from Harvard University and an AB in economics and political science from Stanford University. At Section 32, he joins managing partner Michael Pellini, the former CEO of Foundation Medicine.